Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 15 studies | 28% ± 11% | |
brain | 12 studies | 34% ± 19% | |
lung | 11 studies | 25% ± 6% | |
intestine | 8 studies | 21% ± 6% | |
eye | 7 studies | 22% ± 9% | |
kidney | 4 studies | 20% ± 3% | |
bone marrow | 4 studies | 23% ± 4% | |
liver | 4 studies | 29% ± 11% | |
adipose | 4 studies | 21% ± 2% | |
pancreas | 3 studies | 43% ± 18% | |
uterus | 3 studies | 35% ± 14% | |
lymph node | 3 studies | 26% ± 6% | |
breast | 3 studies | 25% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 6423.23 | 1445 / 1445 | 100% | 70.57 | 183 / 183 |
lung | 100% | 6690.69 | 578 / 578 | 100% | 72.90 | 1155 / 1155 |
ovary | 100% | 7229.08 | 180 / 180 | 100% | 58.84 | 430 / 430 |
breast | 100% | 6814.09 | 459 / 459 | 100% | 102.63 | 1117 / 1118 |
intestine | 100% | 6329.16 | 966 / 966 | 100% | 65.75 | 526 / 527 |
prostate | 100% | 5799.15 | 245 / 245 | 100% | 72.61 | 501 / 502 |
stomach | 100% | 4905.81 | 359 / 359 | 100% | 63.16 | 285 / 286 |
bladder | 100% | 6553.95 | 21 / 21 | 100% | 66.72 | 502 / 504 |
uterus | 100% | 6876.83 | 170 / 170 | 100% | 69.47 | 457 / 459 |
pancreas | 100% | 4068.83 | 328 / 328 | 99% | 60.64 | 177 / 178 |
thymus | 100% | 6421.59 | 653 / 653 | 99% | 68.19 | 600 / 605 |
brain | 99% | 3917.26 | 2609 / 2642 | 100% | 45.73 | 705 / 705 |
kidney | 100% | 4962.96 | 89 / 89 | 98% | 56.41 | 882 / 901 |
liver | 100% | 4161.99 | 226 / 226 | 98% | 42.89 | 397 / 406 |
adrenal gland | 100% | 8354.19 | 258 / 258 | 97% | 55.43 | 223 / 230 |
skin | 100% | 8396.83 | 1809 / 1809 | 97% | 64.61 | 456 / 472 |
adipose | 100% | 7247.83 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7072.30 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 57.30 | 29 / 29 |
muscle | 100% | 8860.07 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5604.99 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 66.29 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 22.66 | 1 / 1 |
heart | 98% | 5596.97 | 841 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 6134.82 | 904 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 94% | 40.30 | 75 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0034982 | Biological process | mitochondrial protein processing |
GO_0097150 | Biological process | neuronal stem cell population maintenance |
GO_0008283 | Biological process | cell population proliferation |
GO_0035694 | Biological process | mitochondrial protein catabolic process |
GO_0010636 | Biological process | positive regulation of mitochondrial fusion |
GO_0009267 | Biological process | cellular response to starvation |
GO_0007005 | Biological process | mitochondrion organization |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_2000035 | Biological process | regulation of stem cell division |
GO_0034214 | Biological process | protein hexamerization |
GO_0006515 | Biological process | protein quality control for misfolded or incompletely synthesized proteins |
GO_0016020 | Cellular component | membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005743 | Cellular component | mitochondrial inner membrane |
GO_0016604 | Cellular component | nuclear body |
GO_0004176 | Molecular function | ATP-dependent peptidase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004222 | Molecular function | metalloendopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | YME1L1 |
Protein name | YME1-like 1 (S. cerevisiae) YME1 like 1 ATPase (YME1L1 protein) YME1 like 1 ATPase ATP-dependent zinc metalloprotease YME1L1 (EC 3.4.24.-) (ATP-dependent metalloprotease FtsH1) (Meg-4) (Presenilin-associated metalloprotease) (PAMP) (YME1-like protein 1) |
Synonyms | FTSH1 YME1L UNQ1868/PRO4304 |
Description | FUNCTION: ATP-dependent metalloprotease that catalyzes the degradation of folded and unfolded proteins with a suitable degron sequence in the mitochondrial intermembrane region . Plays an important role in regulating mitochondrial morphology and function by cleaving OPA1 at position S2, giving rise to a form of OPA1 that promotes maintenance of normal mitochondrial structure and mitochondrial protein metabolism . Ensures cell proliferation, maintains normal cristae morphology and complex I respiration activity, promotes antiapoptotic activity and protects mitochondria from the accumulation of oxidatively damaged membrane proteins . Required for normal, constitutive degradation of PRELID1 . Catalyzes the degradation of OMA1 in response to membrane depolarization . Required to control the accumulation of nonassembled respiratory chain subunits (NDUFB6, OX4 and ND1) . . |
Accessions | Q96TA2 R4GNA5 ENST00000396296.7 ENST00000376016.8 [Q96TA2-2] Q5T8D2 Q6PJ89 ENST00000326799.7 [Q96TA2-1] Q5T8D1 ENST00000427324.5 ENST00000613434.4 [Q96TA2-3] ENST00000477432.1 ENST00000491542.6 Q96I63 |